NASDAQ · Financial Statements
CRISPR Therapeutics AG (CRSP) Financial Statements
$49.25
NASDAQ: CRSP
Market Cap $4.76B
Overview Financials Dividend
CRISPR Therapeutics AG most recently reported annual revenue of $4.0M, a net loss of $582.0M. Revenue grew at an average annual rate of 32.0% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025
Revenue $913.0M $0 $370.0M $35.0M $4.0M Operating Profit $374.0M $-673.0M $-223.0M $-467.0M $-568.0M Net Profit $378.0M $-650.0M $-154.0M $-366.0M $-582.0M EPS $4.70 $-8.36 $-1.94 $-4.34 $-6.47 Op Margin 40.9% -154394.7% -60.1% -1333.0% -16191.4%
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025
Total Assets $2.8B $2.2B $2.2B $2.2B $2.3B Total Liabilities $352.0M $368.0M $347.0M $310.0M $343.0M Cash $923.0M $212.0M $389.0M $298.0M $355.0M Borrowings $225.0M $244.0M $239.0M $224.0M $395.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow $539.0M $-496.0M $-260.0M $-143.0M $-345.0M Investing Cash Flow $-1.1B $-296.0M $365.0M $-282.0M $-33.0M Financing Cash Flow $38.0M $38.0M $0 $31.0M $0 Net Cash Flow $-246.0M $-716.0M $178.0M $-91.0M $49.0M Free Cash Flow $457.0M $-533.0M $-270.0M $-145.0M $-346.0M
Valuation & Return Ratios
Metric Value PEG Ratio -2.59 EV / EBITDA -12.84 FCF Yield -9.01% Quick Ratio 17.85 Interest Coverage — Return 1Y 8.09% Return 3Y 12.65% Return 5Y -53.33%
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .